Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.34 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043555 | 0.98 | CHRM2 (1.00) | CHRM2CHRM3ALDH1A1L3MBTL1ADRA1A | |
| Bromide SCHEMBL194843 | 0.95 | CHRM2 (0.93) | CHRM2CHRM3ALDH1A1L3MBTL1ADRA1A | |
| SCHEMBL17147302 | 0.86 | CHRM2 (0.78) | CHRM2CHRM3L3MBTL1ADRA1AADRA1B | |
| SCHEMBL12787584 | 0.81 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1043522 | 0.81 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1044113 | 0.81 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL18179697 | 0.80 | CHRM2 (0.69) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL10934410 | 0.80 | CHRM2 (0.68) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL12787585 | 0.78 | CHRM2 (0.65) | CHRM2CHRM3ALDH1A1ADRA1AADRA1B | |
| SCHEMBL1042163 | 0.78 | CHRM2 (0.65) | CHRM2CHRM3L3MBTL1ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921790-B1 | SULFONYL FLUORIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV TEXAS (US) | 2004-05-19 | — | — | EP | claimed |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3563849-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10413551-B2 | Combination therapies for the treatment of Alzheimer'S disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-09-17 | — | — | US | disclosed |
| US-10406164-B2 | Combination therapies for the treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-20160158191-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158165-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158192-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20150283113-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| CN-104869993-A | Combination therapy for the treatment of alzheimer's disease and related disorders | GEN HOSPITAL CORP | 2015-08-26 | — | — | CN | disclosed |
| WO-2015061397-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSTPITAL CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| EP-0921790-B1 | SULFONYL FLUORIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV TEXAS (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2002072025-A2 | IMPROVING POSTSYNAPTIC RESPONSE BY A COMBINATION OF 4-MINOPYRIDINE AND AGONIST | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2002-09-19 | — | — | WO | disclosed |
| US-5798392-A | IRREVERSIBLE ACETYLCHOLINESTERASE INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 67/4885CHRM3 81/4885ADRA1A 246/4885 |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 89/4885CHRM3 98/4885ADRA1A 250/4885 |
| US-20160158165-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-20160158191-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | CHRM2 99/4885CHRM3 107/4885ADRA1A 254/4885 |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-20160158192-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | CHRM2 99/4885CHRM3 107/4885ADRA1A 254/4885 |
| US-20150283113-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-10413551-B2 | Combination therapies for the treatment of Alzheimer'S disease and related disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-10406164-B2 | Combination therapies for the treatment of Alzheimer's disease and related disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 99/4885CHRM3 107/4885ADRA1A 254/4885 |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.